Skip to main content
. Author manuscript; available in PMC: 2010 Dec 18.
Published in final edited form as: Cancer Res. 2009 Sep 29;69(19):7662–7671. doi: 10.1158/0008-5472.CAN-09-1693

Figure 2.

Figure 2

  1. Responses of Ewing sarcoma xenografts to CP-751,871, rapamycin or the combination treatment.
  2. Responses of osteosarcoma xenografts to CP-751,871, rapamycin or the combination treatment.

Tumor-bearing mice were treated with CP-751,871 (0.25 mg/mouse twice weekly × 4). Rapamycin (5 mg/kg daily × 5 per week for up to 12 consecutive weeks) or the combination of CP-751,871 and rapamycin. Tumor diameters were measured weekly.

Left panels: Kaplan Meier event free survival (EFS). Control (black), CP-751,871 (green), rapamycin (blue) or CP-751,871 + rapamycin (red). Curves show the probability of mice being event-free (tumor volume < 4-fold that at initiation of treatment) against days post treatment initiation.

Center panels: Growth of individual tumors; Controls (light gray), CP-751,871 treated (black). Right panels: Growth of individual tumors; Rapamycin (light gray), CP-751,871 + rapamycin treated (black).